Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.0995 EUR -0.5% Market Closed
Market Cap: 19m EUR

Intrinsic Value

The intrinsic value of one SIGHT stock under the Base Case scenario is 1.7891 EUR. Compared to the current market price of 0.0995 EUR, Gensight Biologics SA is Undervalued by 94%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SIGHT Intrinsic Value
1.7891 EUR
Undervaluation 94%
Intrinsic Value
Price
Worst Case
Base Case
Best Case
Compare SIGHT to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SIGHT?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Gensight Biologics SA

Current Assets 2.7m
Cash & Short-Term Investments 270k
Receivables 1.4m
Other Current Assets 1m
Non-Current Assets 4.6m
Long-Term Investments 3.9m
PP&E 695k
Intangibles 38k
Other Non-Current Assets 1k
Current Liabilities 25.6m
Accounts Payable 8.6m
Accrued Liabilities 2.6m
Other Current Liabilities 14.4m
Non-Current Liabilities 13.8m
Long-Term Debt 5.1m
Other Non-Current Liabilities 8.8m
Efficiency

Free Cash Flow Analysis
Gensight Biologics SA

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Gensight Biologics SA

Revenue
194k EUR
Operating Expenses
-15.4m EUR
Operating Income
-15.2m EUR
Other Expenses
80k EUR
Net Income
-15.1m EUR
Fundamental Scores

SIGHT Profitability Score
Profitability Due Diligence

Gensight Biologics SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Gensight Biologics SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

SIGHT Solvency Score
Solvency Due Diligence

Gensight Biologics SA's solvency score is 16/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Positive Net Debt
Short-Term Solvency
16/100
Solvency
Score

Gensight Biologics SA's solvency score is 16/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SIGHT Price Targets Summary
Gensight Biologics SA

Wall Street analysts forecast SIGHT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SIGHT is 0.4386 EUR with a low forecast of 0.404 EUR and a high forecast of 0.483 EUR.

Lowest
Price Target
0.404 EUR
306% Upside
Average
Price Target
0.4386 EUR
341% Upside
Highest
Price Target
0.483 EUR
385% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Gensight Biologics SA
does not pay dividends
Shareholder Yield

Current shareholder yield for SIGHT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SIGHT Insider Trading
Buy and sell transactions by insiders